These findings imply NAD+ may be a potential novel therapeutic method in CCH-induced cognitive impairment, and targeting Sirt1/PGC-1α pathway may be a promising treatment strategy in VaD. Here, PPARGC1A is linked to columnar cell hyperplasia of the breast.